(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of 8.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Eyepoint Pharmaceuticals's revenue in 2025 is $56,042,000.On average, 15 Wall Street analysts forecast EYPT's revenue for 2025 to be $2,571,769,821, with the lowest EYPT revenue forecast at $2,009,577,938, and the highest EYPT revenue forecast at $3,843,823,573. On average, 15 Wall Street analysts forecast EYPT's revenue for 2026 to be $1,118,534,769, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $3,251,354,526.
In 2027, EYPT is forecast to generate $6,206,749,775 in revenue, with the lowest revenue forecast at $1,416,145,527 and the highest revenue forecast at $13,655,689,009.